Mitochondrial disorders have emerged as a major cause of inherited human disease. Although the past decade has seen major advances in our understanding of their genetic basis and the underlying pathology, these findings have yet to translate into new therapies. There is a growing appreciation that new treatments will only emerge through a concerted collaboration between clinicians, laboratory scientists and the life sciences industry, based on a firm understanding of the disease mechanisms.